Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Other Operating Income

Other segment segments

AvKARE
$0

Similar metrics at other companies

Corpay logo
CPAYOther — Other Operating Income
-$48K
Asset Entities logo
ASSTCorporate & Other — Other Operating Income
-$295.29M
Better Home & Finance logo
BETRBanking — Other Operating Income
-$3.52M-593%
HF Sinclair logo
DINOMarketing — Other Operating Income
$0
HF Sinclair logo
DINOMidstream — Other Operating Income
$0
HF Sinclair logo
DINORefining — Other Operating Income
$0+100%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Three Months Ended June 30, 2026Affordable Medicines (1)SpecialtyAv KARECorporateand OtherTotal Company
Selling, general and administrative42,36740,09516,91349,347148,722
Research and development33,0235,99439,017
Intellectual property legal development expenses2,002852,087
Acquisition costs7,6007,600
Restructuring and other charges554554
Charges related to legal matters, net8,0578,057
Other operating income(1,298)(1,298)
Operating income (loss)$123,078$54,856$9,336$(57,501)$129,769

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income?
Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — other operating income of $1.3M in Q2 2026.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income has grown at a 9.8% compound annual growth rate (CAGR), from $3.96M to $5.24M.
What does affordable medicines — other operating income mean?
Captures miscellaneous operating income or expenses that do not fall into standard categories like cost of goods sold or SG&A. This includes ancillary revenue streams or minor operational costs essential for assessing the segment's core operational efficiency.

Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude